Skip to main content
  • Home
  •  Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice

Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice

Topic:
  • Heart Failure

Available Credit:

  • 1.00 MMA

Course Published On:

Course Expiry Date:

Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice

Overview

This on-demand programme, Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice, has been developed to further education among practicing cardiologists to ensure understanding of the latest ARNI data in HFpEF and HFrEF, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of ARNI therapy in appropriate heart failure patients.

 

The programme brings together a leading international faculty from Malaysian, US, Germany, Singapore, for a four-part series, featuring eight videos.

 

This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.

Disclosure

In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.

 

This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.

Terms & Conditions

Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA)  for 1 hour of external CPD credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity.

Instructions to Participants

There is no fee for taking part in this online learning activity.

 

Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Learning Objectives

  • Understand the latest ARNI data in HFpEF and HFrEF
  • Understand how emerging data relates to current practice in Malaysia
  • Apply current understanding of ARNI therapy in appropriate heart failure patients

Module

Title

Duration

Speakers

1 Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
2 Meet the Expert Q&A – Local Interpretation of Emerging ARNI Data in HF Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
3 Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs) Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore)
4a Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
4b Clinical questions on ARNI therapy – Chapter 2: ARNI Therapy Mode of Action James L Januzzi (Massachusetts General Hospital, US) Akshay S Desai (Brigham and Women’s Hospital, Boston, MA, US) Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
4c Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) David Morrow (Brigham and Women’s Hospital, US)
4d Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) Rolf Wachter (University of Leipzig, Leipzig, Germany)
4e Clinical questions on ARNI therapy – Chapter 5: Summary Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
1.

Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF

Duration:

Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)

3.

Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs)

Duration:

Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore)

4a.

Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)

4c.

Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) David Morrow (Brigham and Women’s Hospital, US)

4d.

Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) Rolf Wachter (University of Leipzig, Leipzig, Germany)

4e.

Clinical questions on ARNI therapy – Chapter 5: Summary

Duration:

Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)

Speaker

Wan Azman Wan Ahmad

University of Malaya Medical Centre, Kuala Lumpur, Malaysia

Prof Wan Azman Wan Ahmad is Professor and Senior Consultant Cardiologist at University of Malaya Medical Centre, Kuala Lumpur, Malaysia. He currently serves as President of the National Heart Association of Malaysia.

View full profile

Carolyn Lam

National Heart Centre Singapore Duke-NUS, Singapore

Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore.

View full profile

Azmee Mohd Ghazi

National Heart Institute, Kuala Lumpur, MY

Dr Azmee Mohd Ghazi is a Cardiologist at the National Heart Centre, Malaysia, where he serves as Clinical Director for Heart Failure and Heart Transplant.

View full profile

James L Januzzi

Massachusetts General Hospital

Dr James L Januzzi,  is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has an in-depht experience as a teacher and leads a research programme with specific focus on cardiac biomarker testing.

View full profile

Akshay S Desai

Brigham and Women’s Hospital, Boston, MA, US

Prof Akshay Desai is a cardiovascular medicine specialist and the director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions. 

View full profile

David Morrow

Cardiovascular Division, Brisham and Women’s Hospital

Prof David A Morrow the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women's Hospital and a Professor of Medicine at Harvard Medical School. He directs the TIMI Biomarker Program

View full profile

Rolf Wachter

University of Leipzig, Leipzig, Germany

View full profile
1.00 MMA

Related Courses

Implementing Heart Failure Guidelines with Collaborative Care
  • Not accredited

Learning objectives

  • Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
  • Apply latest guideline recommendations to patient cases
  • Describe barriers preventing early initiation of GDMT
  • Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
  • Identify the importance of the nurse/cross-functional team
See more
The Advancing Management of Transthyretin Amyloidosis
  • 1.00 EBAC

Learning objectives

  • To differentiate ATTR phenotypes based on presenting signs and symptoms.
  • To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
  • To recall how to identify disease progression across ATTR-cm.
  • To describe the different disease modifying treatments for ATTR including novel agents.
See more
Overcoming the Challenges in Optimising GDMT in HF
  • Not accredited

Learning objectives

  • Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
  • Recognise barriers preventing the use of GDMT in current practice.
  • Identify strategies needed to drive implementation of GDMT in clinical practice.
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more
Incorporating GDMT and PRO Endpoints for Personalised HF Management
  • 1.00 EBAC

Learning objectives

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations
  • Recall the elements of the Kansas City Cardiomyopathy Questionnaire
  • Describe the clinical studies that support the use of functional and QoL measures in practice
  • Initiate quality of life and functional improvement measures in routine practice
  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients
See more
Changing Paradigms in Therapy to Unmet Needs
  • 1.00 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response 
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy 
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF 
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice 
See more
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now
  • Not accredited

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more